Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Irinotécan")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 1863

  • Page / 75
Export

Selection :

  • and

Image-based evaluations of distribution and cytotoxicity of Irinotecan (CPT-11) in a multi-compartment micro-cell coculture deviceNAKAYAMA, Hidenari; KIMURA, Hiroshi; FUJII, Teruo et al.Journal of bioscience and bioengineering. 2014, Vol 117, Num 6, pp 756-762, issn 1389-1723, 7 p.Article

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese : roles of UGT1A1*6 and *28MINAMI, Hironobu; SAI, Kimie; SHIRAO, Kuniaki et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 7, pp 497-504, issn 1744-6872, 8 p.Article

Mechanisms of resistance to topoisomerase I-targeting drugsRASHEED, Zeshaan A; RUBIN, Eric H.Oncogene (Basingstoke). 2003, Vol 22, Num 47, pp 7296-7304, issn 0950-9232, 9 p.Article

Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patientsXIAOQIANG XIANG; RAO JADA, Srinivasa; ENG HUAT TAN et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 9, pp 683-691, issn 1744-6872, 9 p.Article

Expression of drug pathway proteins is independent of tumour typeZHANG, W; SHANNON, W. D; DUNCAN, J et al.Journal of pathology. 2006, Vol 209, Num 2, pp 213-219, issn 0022-3417, 7 p.Article

Adding pharmacogenetics information to drug labels: lessons learnedHAGA, Susanne B; THUMMEL, Kenneth E; BURKE, Wylie et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 12, pp 847-854, issn 1744-6872, 8 p.Article

Bevacizumab and irinotecan for recurrent oligodendroglial tumorsTAILLIBERT, S; VINCENT, L. A; DEHAIS, C et al.Neurology. 2009, Vol 72, Num 18, pp 1601-1606, issn 0028-3878, 6 p.Article

Metabolism of irinotecan (CPT-11) by human hepatic microsomes : Participation of cytochrome P-450 3A and drug interactionsHAAZ, M.-C; RIVORY, L; RICHE, C et al.Cancer research (Baltimore). 1998, Vol 58, Num 3, pp 468-472, issn 0008-5472Article

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecanVAN ERP, Nielka P. H; BAKER, Sharyn D; MING ZHAO et al.Clinical cancer research. 2005, Vol 11, Num 21, pp 7800-7806, issn 1078-0432, 7 p.Article

Irinotecan in combination with new agentsVANHOEFER, U; ROUGIER, P; BORNER, M et al.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 7, pp 14-20, issn 1359-6349, 7 p.Conference Paper

Salvage chemotherapy With CPT-11 for recurrent meningiomaCHAMBERLAIN, Marc C; TSAO-WEI, Denice D; GROSHEN, Susan et al.Journal of neuro-oncology. 2006, Vol 78, Num 3, pp 271-276, issn 0167-594X, 6 p.Article

Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variabilityDE JONG, Floris A; MATHIJSSEN, Ron H. J; RUJIA XIE et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4068-4071, issn 1078-0432, 4 p., 1Article

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecanSAI, Kimie; KANIWA, Nahoko; MINAMI, Hironobu et al.Pharmacogenetics (London). 2003, Vol 13, Num 12, pp 741-757, issn 0960-314X, 17 p.Article

Actualités sur le CPT-11 à l'ASCO 2003 = CPT-11 AT ASCO 2003SPANO, J. P; ATLAN, D; BOIGE, V et al.La Lettre du cancérologue (Boulogne). 2003, Vol 12, Num 3, pp 1-7, issn 1165-113X, 7 p., SUPArticle

Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d'une étude multicentrique de l'Anocef = Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas : Preliminary results of an ANOCEF Multicenter StudyGUIU, S; TAILLIBERT, S; CAPELLE, F et al.Revue neurologique (Paris). 2008, Vol 164, Num 6-7, pp 588-594, issn 0035-3787, 7 p.Article

Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomesDICKO, Awa; TARDI, Paul; XIAOWEI XIE et al.International journal of pharmaceutics. 2007, Vol 337, Num 1-2, pp 219-228, issn 0378-5173, 10 p.Article

Insights, challenges, and future directions in irinogeneticsTAE WON KIM; INNOCENTI, Federico.Therapeutic drug monitoring. 2007, Vol 29, Num 3, pp 265-270, issn 0163-4356, 6 p.Article

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly scheduleGARCIA, Agustin A; PUJARI, Mahesh; JEFFERS, Susan et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 1, pp 75-82, issn 0344-5704, 8 p.Article

Effects of green tea compounds on irinotecan metabolismMIRKOV, Snezana; KOMOROSKI, Bernard J; RAMIREZ, Jacqueline et al.Drug metabolism and disposition. 2007, Vol 35, Num 2, pp 228-233, issn 0090-9556, 6 p.Article

5-fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome : report of a caseSTEINER, M; SEULE, M; STEINER, B et al.Journal of clinical pathology. 2005, Vol 58, Num 5, pp 553-555, issn 0021-9746, 3 p.Article

Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genesINNOCENTI, Federico; WANQING LIU; PEIXIAN CHEN et al.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 5, pp 295-301, issn 1744-6872, 7 p.Article

Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissueITAGAKI, Shirou; SUMI, Yoshinobu; SHIMAMOTO, Soji et al.Cancer chemotherapy and pharmacology. 2005, Vol 55, Num 5, pp 502-506, issn 0344-5704, 5 p.Article

A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancerAGELAKI, Sofia; SYRIGOS, Kostas; MILAKI, Georgia et al.Oncology. 2004, Vol 66, Num 3, pp 192-196, issn 0030-2414, 5 p.Article

Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11)PALMER, Roger David; WILLIAMS, Denise Mary.Medical and pediatric oncology. 2003, Vol 41, Num 1, pp 78-80, issn 0098-1532, 3 p.Article

Irinotecan drug eluting beads for use in chemoembolization : In vitro and in uiuo evaluation of drug release propertiesTAYLOR, Rachel R; YIQING TANG; GONZALEZ, M. Victoria et al.European journal of pharmaceutical sciences. 2007, Vol 30, Num 1, pp 7-14, issn 0928-0987, 8 p.Article

  • Page / 75